<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01894152</url>
  </required_header>
  <id_info>
    <org_study_id>12-396</org_study_id>
    <nct_id>NCT01894152</nct_id>
  </id_info>
  <brief_title>XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study</brief_title>
  <acronym>XP China SAS</acronym>
  <official_title>Evaluate the Continued Safety and Effectiveness of the XIENCE PRIME EECSS in a Cohort of Real-world Patients Receiving the XIENCE PRIME EECSS During Commercial Use.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abbott Vascular (AV) obtained marketing approval for the XIENCE PRIME Everolimus Eluting
      Coronary Stent System (XIENCE PRIME EECSS) in China from the China Food and Drug
      Administration (CFDA) on August 10th, 2011.

      This prospective, observational, open-label, multi-center, single-arm, post-approval study is
      designed to evaluate the continued safety and effectiveness of the XIENCE PRIME EECSS in a
      cohort of real-world patients receiving the XIENCE PRIME EECSS during commercial use in
      real-world settings in China.

      This study has no primary outcome measure. All observations are of equal weight.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite rate of cardiac death and all myocardial infarction (MI) (Q-wave and non-Qwave)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite rate of cardiac death and all myocardial infarction (MI) (Q-wave and non-Qwave)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite rate of cardiac death and all myocardial infarction (MI) (Q-wave and non-Qwave)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite rate of cardiac death and all myocardial infarction (MI) (Q-wave and non-Qwave)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite rate of cardiac death and all myocardial infarction (MI) (Q-wave and non-Qwave)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite rate of all death and all myocardial infarction (MI) (Q-wave and non-Q-wave)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite rate of all death and all myocardial infarction (MI) (Q-wave and non-Q-wave)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite rate of all death and all myocardial infarction (MI) (Q-wave and non-Q-wave)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite rate of all death and all myocardial infarction (MI) (Q-wave and non-Q-wave)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite rate of all death and all myocardial infarction (MI) (Q-wave and non-Q-wave)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Target lesion failure (TLF): the composite rate of cardiac death, target vessel MI (TVMI), and ischemia-driven target lesion revascularization (ID-TLR)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Target lesion failure (TLF): the composite rate of cardiac death, target vessel MI (TVMI), and ischemia-driven target lesion revascularization (ID-TLR)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Target lesion failure (TLF): the composite rate of cardiac death, target vessel MI (TVMI), and ischemia-driven target lesion revascularization (ID-TLR)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Target lesion failure (TLF): the composite rate of cardiac death, target vessel MI (TVMI), and ischemia-driven target lesion revascularization (ID-TLR)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Target lesion failure (TLF): the composite rate of cardiac death, target vessel MI (TVMI), and ischemia-driven target lesion revascularization (ID-TLR)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Target vessel failure (TVF): the composite rate of cardiac death, all MI, and ischemia driven target vessel revascularization (ID-TVR)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Target vessel failure (TVF): the composite rate of cardiac death, all MI, and ischemia driven target vessel revascularization (ID-TVR)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Target vessel failure (TVF): the composite rate of cardiac death, all MI, and ischemia driven target vessel revascularization (ID-TVR)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Target vessel failure (TVF): the composite rate of cardiac death, all MI, and ischemia driven target vessel revascularization (ID-TVR)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Target vessel failure (TVF): the composite rate of cardiac death, all MI, and ischemia driven target vessel revascularization (ID-TVR)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent thrombosis (definite and probable, per Academic Research Consortium[ARC] definition)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent thrombosis (definite and probable, per Academic Research Consortium[ARC] definition)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent thrombosis (definite and probable, per Academic Research Consortium[ARC] definition)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent thrombosis (definite and probable, per Academic Research Consortium [ARC] definition)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent thrombosis (definite and probable, per Academic Research Consortium[ARC] definition)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death (cardiac, vascular, and non-cardiovascular)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death (cardiac, vascular, and non-cardiovascular)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death (cardiac, vascular, and non-cardiovascular)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death (cardiac, vascular, and non-cardiovascular)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death (cardiac, vascular, and non-cardiovascular)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All MI (including Q-wave and non-Q-wave)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All MI (including Q-wave and non-Q-wave)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All MI (including Q-wave and non-Q-wave)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All MI (including Q-wave and non-Q-wave)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All MI (including Q-wave and non-Q-wave)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Revascularization (target lesion, target vessel, and non-target vessel) (PCI and Coronary Artery Bypass Graft [CABG])</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Revascularization (target lesion, target vessel, and non-target vessel) (PCI and Coronary Artery Bypass Graft [CABG])</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Revascularization (target lesion, target vessel, and non-target vessel) (PCI and Coronary Artery Bypass Graft [CABG])</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Revascularization (target lesion, target vessel, and non-target vessel) (PCI and Coronary Artery Bypass Graft [CABG])</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Revascularization (target lesion, target vessel, and non-target vessel) (PCI and Coronary Artery Bypass Graft [CABG])</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2003</enrollment>
  <condition>Angioplasty</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Heart Disease</condition>
  <condition>Coronary Restenosis</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Stent Thrombosis</condition>
  <condition>Vascular Disease</condition>
  <arm_group>
    <arm_group_label>XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)</arm_group_label>
    <description>Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)</intervention_name>
    <description>Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)</description>
    <arm_group_label>XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort of real-world patients receiving the XIENCE PRIME EECSS during commercial use in
        realworld settings in China.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must be at least 18 years of age at the time of signing the informed
             consent.

          -  The patient or his/her legally-authorized representative signs the EC-approved
             Informed Consent Form (ICF).

          -  Only XIENCE PRIME stent(s) is (are) implanted during the index procedure.

        Exclusion Criteria:

          -  No other exclusion criteria are specified for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, MB, MSc, MD, FACC, FESC, FSCAI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fang Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anzhen Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abbott Vascular</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2013</study_first_submitted>
  <study_first_submitted_qc>July 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XIENCE PRIME EECSS</keyword>
  <keyword>XIENCE V EECSS</keyword>
  <keyword>XIENCE PRIME</keyword>
  <keyword>SPIRIT PRIME</keyword>
  <keyword>XIENCE PRIME SV (Small Vessel)</keyword>
  <keyword>XIENCE PRIME LL (Long Lesion)</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Stent Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 16, 2017</submitted>
    <returned>September 13, 2017</returned>
    <submitted>April 9, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

